Peter Ciano named Tris Pharma's VP corporate development
MONMOUTH JUNCTION, N.J. A specialty pharmaceutical company that develops innovative drug delivery technologies has appointed a new VP corporate development.
Tris Pharma said Peter Ciano, who currently is a business development consultant for the company, now will lead and manage Tris' lead all commercial efforts including business development, licensing, identifying growth opportunities and deal executions for its brand side of the business.
"As our technology gains wider acceptance for both Rx and OTC branded businesses, we are increasingly faced with the need for intelligent pursuit of the products and opportunities. Peter's solid analytical approach coupled with his deep understanding of pharmaceutical marketer's needs and health care provider's requirement for reimbursement makes him uniquely qualified to guide and lead Tris in this position," said Ketan Mehta, founder and CEO of Tris Pharma.
Prior to joining Tris, Ciano worked at Kos Pharmaceuticals (prior to its acquisition by Abbott) for nearly six years, including two years as its executive director of corporate development and business planning.
Most recently, Tris had announced FDA had approval two NDAs including first-ever 24-hour ER suspension. Tris has an active portfolio of more than 20 OTC and Rx products based on its proprietary technology.